Cullinan Therapeutics, Inc. - COMMON STOCK (CGEM)

CUSIP: 230031106

Q1 2024 13F Holders as of 31 Mar 2024

Holder snapshot 7 signals
Share change
+2,521,442
Put/Call ratio
39%
SEC-reported price per share
$17.04
Indexed holders
113
Value change
+$49,224,262
Number of buys
57
Open additional details 1 more signal available
Number of sells
56
Security identity Names, identifiers, and filing context for this profile. 1 source field
Shares outstanding
65,102,625

Security key

230031106

Report period

Q1 2024

Indexed institutions

113

Top holders

10

Ownership snapshot

Top reported holders of CGEM - Cullinan Therapeutics, Inc. - COMMON STOCK (13F + 13D/G + 3/4/5)

Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.

Comparable stake leader
UBS Oncology Impact Fund ...
Disclosed value leader
Ansbert Gadicke
Comparable rows
0/15
Latest evidence
31 Dec 2023
3/4/5 13F Highest disclosed value: $102,717,212 15 rows are not safely comparable across share classes. Showing 1-6 of 15 holder rows.

Quick read

Ansbert Gadicke has the largest disclosed position value at $102.72M.

0 of 15 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.

Open SEC evidence Opens Ansbert Gadicke's linked filing trail.
Disclosed position value Top 5
UBS Oncology Impact Fund L.P. $95.3M
Morana Jovan-Embiricos $56.4M
Vision Scs F2 $55.78M
F2 Bioscience I 2017 Ltd $55.21M
BVF PARTNERS L P/IL $799.4K

Value bars compare disclosed positions; verify each figure against the linked filing evidence.

Detailed SEC evidence table Showing 1-6 of 15 holder rows
Holder Evidence Ownership % Position 12M Net Δ As of
UBS Oncology Impact Fund L.P.
3/4/5
10%+ Owner
—
denominator unverified
$95,297,419
7,648,268 shares
— 16 Sep 2021
Morana Jovan-Embiricos
3/4/5
10%+ Owner
—
denominator unverified
$56,397,201
4,526,260 shares
— 24 Jun 2022
Vision Scs F2
3/4/5
10%+ Owner
—
denominator unverified
$55,775,322
4,476,350 shares
— 02 Aug 2022
F2 Bioscience I 2017 Ltd
3/4/5
10%+ Owner
—
denominator unverified
$55,209,813
4,430,964 shares
— 21 Jun 2022
BVF PARTNERS L P/IL
3/4/5
10%+ Owner
—
mixed-class rows
$799,446
94,161 shares
mixed-class rows
— 19 Jan 2023
Ansbert Gadicke
3/4/5
Director
—
denominator unverified
$102,717,212
8,243,757 shares
— 22 Jun 2022
How to read this table

Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.

13F holder rows

Institutional holders as of Q1 2024

Investor-level positions for this CUSIP, loaded as an interactive table.

Indexed institutions
113
Shares
39,359,979
Indexed holders
113
Investor Option Weight % Change % SEC-reported value * Price Shares Share Change Activity Report Period

* SEC-reported price is the security price as of the portfolio date and can indicate the last known price at which the security was still held. The marker flags a reported price that did not pass the local price check.

Reported share positions only; options and principal amounts are excluded. Missing manager disclosures are unavailable, not zero. A missing position becomes zero only when complete coverage is verified for both snapshots. Counts describe the indexed universe; the comparison may cover a smaller set.

Compare Q1 2024 vs Q4 2023 Across Filers

Q4 2023 indexed holders
110
Q1 2024 indexed holders
113
Indexed holder difference
3
Investor Q4 2023 Shares Q1 2024 Shares Share Diff Share Chg % Q4 2023 value Q1 2024 value Value change Value Chg %

Trend: the last eight indexed quarters, including the selected comparison periods.

Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend
We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .